JP2017014206A - 腹水の治療 - Google Patents

腹水の治療 Download PDF

Info

Publication number
JP2017014206A
JP2017014206A JP2016128584A JP2016128584A JP2017014206A JP 2017014206 A JP2017014206 A JP 2017014206A JP 2016128584 A JP2016128584 A JP 2016128584A JP 2016128584 A JP2016128584 A JP 2016128584A JP 2017014206 A JP2017014206 A JP 2017014206A
Authority
JP
Japan
Prior art keywords
ascites
patient
continuous infusion
salt
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016128584A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017014206A5 (en:Method
Inventor
アンジェリ，パオロ，エムディー
Md Angeli Paolo
マーカム，ペニー
Markham Penelope
アダムズ，ジョナサン
Adams Jonathan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Of Padova, University of
Biovie Inc
Original Assignee
Of Padova, University of
Nanoantibiotics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57609113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2017014206(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Of Padova, University of, Nanoantibiotics Inc filed Critical Of Padova, University of
Publication of JP2017014206A publication Critical patent/JP2017014206A/ja
Publication of JP2017014206A5 publication Critical patent/JP2017014206A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
JP2016128584A 2015-06-30 2016-06-29 腹水の治療 Pending JP2017014206A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562186638P 2015-06-30 2015-06-30
US62/186,638 2015-06-30
US201562267510P 2015-12-15 2015-12-15
US62/267,510 2015-12-15
US201662321558P 2016-04-12 2016-04-12
US62/321,558 2016-04-12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018145654A Division JP2018172440A (ja) 2015-06-30 2018-08-02 腹水の治療

Publications (2)

Publication Number Publication Date
JP2017014206A true JP2017014206A (ja) 2017-01-19
JP2017014206A5 JP2017014206A5 (en:Method) 2017-08-31

Family

ID=57609113

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2016128584A Pending JP2017014206A (ja) 2015-06-30 2016-06-29 腹水の治療
JP2018145654A Pending JP2018172440A (ja) 2015-06-30 2018-08-02 腹水の治療
JP2020115254A Pending JP2020172520A (ja) 2015-06-30 2020-07-03 腹水の治療
JP2022107055A Pending JP2022136104A (ja) 2015-06-30 2022-07-01 腹水の治療
JP2023133333A Pending JP2023160839A (ja) 2015-06-30 2023-08-18 腹水の治療
JP2025107051A Pending JP2025143324A (ja) 2015-06-30 2025-06-25 腹水の治療

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2018145654A Pending JP2018172440A (ja) 2015-06-30 2018-08-02 腹水の治療
JP2020115254A Pending JP2020172520A (ja) 2015-06-30 2020-07-03 腹水の治療
JP2022107055A Pending JP2022136104A (ja) 2015-06-30 2022-07-01 腹水の治療
JP2023133333A Pending JP2023160839A (ja) 2015-06-30 2023-08-18 腹水の治療
JP2025107051A Pending JP2025143324A (ja) 2015-06-30 2025-06-25 腹水の治療

Country Status (7)

Country Link
US (6) US9655945B2 (en:Method)
EP (2) EP3347032B1 (en:Method)
JP (6) JP2017014206A (en:Method)
CN (2) CN120324576A (en:Method)
ES (1) ES2971959T3 (en:Method)
HK (1) HK1258611A1 (en:Method)
WO (1) WO2017004317A1 (en:Method)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020172520A (ja) * 2015-06-30 2020-10-22 ナノアンティバイオティクス，インコーポレイテッド 腹水の治療

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0918652B1 (pt) 2008-09-17 2021-10-19 Chiasma, Inc. Composição farmacêutica compreendendo um meio hidrofóbico e uma forma sólida que compreende polipeptídeo e sal de ácido graxo de cadeia média, processo de produção da mesma e forma de dosagem oral
DK3978074T3 (da) 2014-10-24 2024-05-13 Mallinckrodt Pharmaceuticals Ireland Ltd Terlipressin til behandling af hepatorenalt syndrom type 1
HUE071943T2 (hu) 2015-02-03 2025-10-28 Amryt Endo Inc Akromegália kezelése oktreotid orális alkalmazásával
EP3528828B1 (en) 2016-10-21 2025-01-29 Amryt Endo, Inc. Terlipressin composition for use in treating ascites
CN112704727B (zh) * 2021-01-12 2023-05-16 重庆医科大学附属第二医院 特利加压素在制备动力性肠梗阻药物中的应用
CN113077888A (zh) * 2021-03-30 2021-07-06 福州宜星大数据产业投资有限公司 自动化meld评分方法、终端及存储介质
WO2023150254A1 (en) * 2022-02-03 2023-08-10 Biovie Inc. Methods of treating disease with terlipressin

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040102362A1 (en) * 2000-09-15 2004-05-27 Didier Lebrec Protocol for paracentesis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1984012T3 (pl) * 2006-02-13 2016-07-29 Ferring Bv Zastosowanie peptydowych agonistów receptora wazopresyny
WO2009037586A2 (en) * 2007-08-14 2009-03-26 Ferring B.V. Use of peptidic vasopressin receptor agonists
EP2203172A2 (en) * 2007-09-28 2010-07-07 Ferring B.V. Use of v2 receptor antagonists in combination with vasopressinergic agonists
EP2214709A4 (en) * 2007-11-08 2011-05-11 Univ Utah Res Found USE OF ANGIOGENESIS ANTAGONISTS IN DISEASES WITH ANOMAL VENEER PREPARATION
US8815232B2 (en) 2008-08-26 2014-08-26 Kyon Biotech Ag Compositions and methods for treating cancer
EP2406399B1 (en) * 2009-03-09 2018-02-14 Bioatla, LLC Mirac proteins
MX375116B (es) * 2009-06-08 2025-03-06 Ucl Business Plc Tratamiento de hipertension portal y restauracion de la funcion hepatica usando fenilacetato de l-ornitina.
EP2593541A4 (en) * 2010-07-14 2014-01-22 Cumberland Emerging Technologies Inc METHOD FOR THE TREATMENT OF HEPATORENAL SYNDROME AND HEPATIC ENZEPHALOPATHY WITH THROMBOXANE A2 RECEPTOR ANTAGONISTS
WO2013106072A1 (en) 2012-01-10 2013-07-18 Sorbent Therapeutics, Inc. Compositions comprising crosslinked cation-binding polymers and uses thereof
JO3109B1 (ar) 2012-05-10 2017-09-20 Ferring Bv منبهات لمستقبلات v1a
CN102731625B (zh) * 2012-06-27 2014-10-15 深圳翰宇药业股份有限公司 一种纯化特利加压素的方法
WO2014075082A1 (en) 2012-11-12 2014-05-15 Gregory Thomas Everson Disease severity index for assessment of chronic liver disease and method for diagnosis of three distinct subtypes of primary sclerosing cholangitis
CN105592855A (zh) * 2013-04-26 2016-05-18 拉卓拉药物公司 用于治疗肾衰竭的组合物和方法
CN104510840A (zh) 2013-08-21 2015-04-15 乔治亚摄政研究学院有限公司 改性绿茶多酚和其用于治疗肝病的方法
JP2017014206A (ja) * 2015-06-30 2017-01-19 ナノアンティバイオティクス，インコーポレイテッド 腹水の治療

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040102362A1 (en) * 2000-09-15 2004-05-27 Didier Lebrec Protocol for paracentesis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EXPERT OPINION ON ORPHAN DRUGS, vol. 1, no. 3, JPN6017033245, 2013, pages 241 - 248, ISSN: 0003770161 *
HEPATOLOGY, vol. 60, JPN6017033241, 2014, pages 2125 - 2126, ISSN: 0003770160 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020172520A (ja) * 2015-06-30 2020-10-22 ナノアンティバイオティクス，インコーポレイテッド 腹水の治療
JP2022136104A (ja) * 2015-06-30 2022-09-15 ナノアンティバイオティクス，インコーポレイテッド 腹水の治療

Also Published As

Publication number Publication date
HK1258611A1 (zh) 2019-11-15
EP3347032A4 (en) 2019-06-19
US20180000887A1 (en) 2018-01-04
US9655945B2 (en) 2017-05-23
WO2017004317A1 (en) 2017-01-05
EP3347032B1 (en) 2023-11-29
JP2018172440A (ja) 2018-11-08
US20240165193A1 (en) 2024-05-23
ES2971959T3 (es) 2024-06-10
EP4338795A2 (en) 2024-03-20
JP2025143324A (ja) 2025-10-01
US11364277B2 (en) 2022-06-21
US20170000844A1 (en) 2017-01-05
EP4338795A3 (en) 2024-08-28
US20190365848A1 (en) 2019-12-05
CN106999539A (zh) 2017-08-01
US20250312410A1 (en) 2025-10-09
JP2020172520A (ja) 2020-10-22
US20230146264A1 (en) 2023-05-11
JP2023160839A (ja) 2023-11-02
CN120324576A (zh) 2025-07-18
JP2022136104A (ja) 2022-09-15
EP3347032A1 (en) 2018-07-18

Similar Documents

Publication Publication Date Title
JP2018172440A (ja) 腹水の治療
RU2015134581A (ru) Доноры нитроксила с улучшенным терапевтическим индексом
JP2019514974A5 (en:Method)
JP2017501154A5 (en:Method)
JP2016517421A5 (en:Method)
Fink et al. A severe case of haemodynamic instability during anidulafungin administration.
Saraceno et al. Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: a report of two cases
CN112930191A (zh) 乳酸盐保护的低糖血治疗糖酵解依赖性病理状况特别是癌症
Tüfek et al. Immediate cardiac arrest after neostigmine administration
CN102205115B (zh) 乌司他丁作为急腹症引起的中毒性休克的抢救辅助药物的用途
Poca et al. 104 RENAL FAILURE AND MORTALITY IN CIRRHOTIC PATIENTS WITH SPONTANEOUS BACTERIAL PERITONITIS AND LOW RISK OF MORTALITY NON-TREATED WITH ALBUMIN
WO2016139740A1 (ja) 肝線維化改善剤
CN103285378A (zh) Glp-1用于制备预防与治疗2型糖尿病性心肌病的药物的用途
Yamane Cardiac arrest in a child due to inadvertent intravascular administration: case report
CN103356677B (zh) Houttuynoid D在制备治疗或预防急性心衰的药物中的应用
Alessandria et al. 103 RELATIVE ADRENAL INSUFFICIENCY IN CIRRHOSIS: RELEVANCE IN PATIENTS WITH ASCITES AND TREATMENT WITH HYDROCORTISONE IN REFRACTORY ASCITES
CN103356686B (zh) Houttuynoid B在制备治疗或预防慢性心衰的药物中的应用
Janssen Continuous intraperitoneal insulin infusion (CIPII) for type 1 diabetes: Effective therapy but a case of bad timing?
JP2016210733A (ja) ガン予防または治療用医薬組成物
Admani Convulsions, and cardiovascular complications treated with soya oil emulsion, in an infant: case report
Yamada Aspirin/heparin
Berlin et al. 1723: ACQUIRED VON WILLEBRAND DISEASE IN ESSENTIAL THROMBOCYTHEMIA
Shanbhag et al. 1725: ACUTE INTERMITTENT PORPHYRIA: A CHALLENGING DIAGNOSIS
Myler et al. 1724: HEMOPHILIA A TREATED WITH SINGLE-DOSE FACTOR VIII REPLACEMENT FOR LIVER TRANSPLANTATION
Rendina et al. SELECTIVE BILIRUBIN APHERESIS IN THE MANAGEMENT OF PATIENTS WITH ACUTE ON CHRONIC LIVER DECOMPENSATION AND PATIENTS WITH LIVER TRANSPLANTATION

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170720

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170720

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20170720

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20170802

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180402